|
31.3.2023 |
EN |
Official Journal of the European Union |
C 118/1 |
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 February 2023 to 28 February 2023
(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1) or Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council (2))
(2023/C 118/01)
— Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
INN (International Non-Proprietary Name) |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Pharmaceutical form |
ATC code (Anatomical Therapeutic Chemical Code) |
Date of notification |
||
|
15.2.2023 |
Dimethyl Fumarate Accord |
dimethyl fumarate |
|
EU/1/22/1711 |
Gastro-resistant capsule, hard |
L04AX07 |
17.2.2023 |
||
|
20.2.2023 |
Hemgenix |
etranacogene dezaparvovec |
|
EU/1/22/1715 |
Concentrate for solution for infusion |
B06 |
23.2.2023 |
||
|
20.2.2023 |
IMJUDO |
tremelimumab |
|
EU/1/22/1713 |
Concentrate for solution for infusion |
L01FX20 |
23.2.2023 |
||
|
20.2.2023 |
Tremelimumab AstraZeneca |
tremelimumab |
|
EU/1/22/1712 |
Concentrate for solution for infusion |
L01FX20 |
21.2.2023 |
||
|
24.2.2023 |
Paxlovid |
Nirmatrelvir / ritonavir |
|
EU/1/22/1625 |
Film-coated tablet |
J05AE30 |
27.2.2023 |
— Modification of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
|
3.2.2023 |
Ambirix |
|
EU/1/02/224 |
6.2.2023 |
||
|
3.2.2023 |
Bortezomib Hospira |
|
EU/1/16/1114 |
6.2.2023 |
||
|
3.2.2023 |
Copiktra |
|
EU/1/21/1542 |
17.2.2023 |
||
|
3.2.2023 |
Darunavir Mylan |
|
EU/1/16/1140 |
7.2.2023 |
||
|
3.2.2023 |
EVOTAZ |
|
EU/1/15/1025 |
6.2.2023 |
||
|
3.2.2023 |
Forxiga |
|
EU/1/12/795 |
6.2.2023 |
||
|
3.2.2023 |
Glivec |
|
EU/1/01/198 |
7.2.2023 |
||
|
3.2.2023 |
HALAVEN |
|
EU/1/11/678 |
8.2.2023 |
||
|
3.2.2023 |
Infanrix hexa |
|
EU/1/00/152 |
17.2.2023 |
||
|
3.2.2023 |
Invanz |
|
EU/1/02/216 |
9.2.2023 |
||
|
3.2.2023 |
KANJINTI |
|
EU/1/18/1281 |
6.2.2023 |
||
|
3.2.2023 |
Levetiracetam Accord |
|
EU/1/11/712 |
6.2.2023 |
||
|
3.2.2023 |
Nimvastid |
|
EU/1/09/525 |
14.2.2023 |
||
|
3.2.2023 |
NULIBRY |
|
EU/1/22/1684 |
9.2.2023 |
||
|
3.2.2023 |
Orencia |
|
EU/1/07/389 |
6.2.2023 |
||
|
3.2.2023 |
Pemetrexed Accord |
|
EU/1/15/1071 |
7.2.2023 |
||
|
3.2.2023 |
Quofenix |
|
EU/1/19/1393 |
8.2.2023 |
||
|
3.2.2023 |
Rasilez |
|
EU/1/07/405 |
13.2.2023 |
||
|
3.2.2023 |
Rixubis |
|
EU/1/14/970 |
9.2.2023 |
||
|
3.2.2023 |
SCENESSE |
|
EU/1/14/969 |
7.2.2023 |
||
|
3.2.2023 |
Sivextro |
|
EU/1/15/991 |
6.2.2023 |
||
|
3.2.2023 |
TRISENOX |
|
EU/1/02/204 |
7.2.2023 |
||
|
3.2.2023 |
Xagrid |
|
EU/1/04/295 |
6.2.2023 |
||
|
3.2.2023 |
Xigduo |
|
EU/1/13/900 |
6.2.2023 |
||
|
6.2.2023 |
Ebvallo |
|
EU/1/22/1700 |
7.2.2023 |
||
|
6.2.2023 |
Ebymect |
|
EU/1/15/1051 |
7.2.2023 |
||
|
6.2.2023 |
Hefiya |
|
EU/1/18/1287 |
7.2.2023 |
||
|
6.2.2023 |
Kerendia |
|
EU/1/21/1616 |
7.2.2023 |
||
|
6.2.2023 |
Tivicay |
|
EU/1/13/892 |
7.2.2023 |
||
|
6.2.2023 |
Xromi |
|
EU/1/19/1366 |
13.2.2023 |
||
|
9.2.2023 |
AMGLIDIA |
|
EU/1/18/1279 |
14.2.2023 |
||
|
9.2.2023 |
Brukinsa |
|
EU/1/21/1576 |
10.2.2023 |
||
|
9.2.2023 |
Tecentriq |
|
EU/1/17/1220 |
13.2.2023 |
||
|
15.2.2023 |
ASPAVELI |
|
EU/1/21/1595 |
17.2.2023 |
||
|
15.2.2023 |
Fulphila |
|
EU/1/18/1329 |
16.2.2023 |
||
|
15.2.2023 |
Hyrimoz |
|
EU/1/18/1286 |
20.2.2023 |
||
|
15.2.2023 |
JEMPERLI |
|
EU/1/21/1538 |
20.2.2023 |
||
|
15.2.2023 |
Lokelma |
|
EU/1/17/1173 |
16.2.2023 |
||
|
15.2.2023 |
Paxlovid |
|
EU/1/22/1625 |
16.2.2023 |
||
|
15.2.2023 |
Pemetrexed Krka |
|
EU/1/18/1283 |
20.2.2023 |
||
|
15.2.2023 |
Pregabalin Sandoz |
|
EU/1/15/1011 |
6.3.2023 |
||
|
15.2.2023 |
Semglee |
|
EU/1/18/1270 |
16.2.2023 |
||
|
15.2.2023 |
Trodelvy |
|
EU/1/21/1592 |
16.2.2023 |
||
|
15.2.2023 |
Vyndaqel |
|
EU/1/11/717 |
16.2.2023 |
||
|
15.2.2023 |
Zonegran |
|
EU/1/04/307 |
21.2.2023 |
||
|
20.2.2023 |
Aimovig |
|
EU/1/18/1293 |
22.2.2023 |
||
|
20.2.2023 |
Calquence |
|
EU/1/20/1479 |
21.2.2023 |
||
|
20.2.2023 |
Tractocile |
|
EU/1/99/124 |
3.3.2023 |
||
|
20.2.2023 |
Triumeq |
|
EU/1/14/940 |
21.2.2023 |
||
|
20.2.2023 |
Yuflyma |
|
EU/1/20/1513 |
21.2.2023 |
||
|
23.2.2023 |
Atosiban SUN |
|
EU/1/13/852 |
27.2.2023 |
||
|
23.2.2023 |
Gilenya |
|
EU/1/11/677 |
24.2.2023 |
||
|
23.2.2023 |
Ivabradine Accord |
|
EU/1/17/1190 |
24.2.2023 |
||
|
23.2.2023 |
Kinzalmono |
|
EU/1/98/091 |
24.2.2023 |
||
|
23.2.2023 |
Micardis |
|
EU/1/98/090 |
2.3.2023 |
||
|
23.2.2023 |
Nimenrix |
|
EU/1/12/767 |
24.2.2023 |
||
|
23.2.2023 |
Pemazyre |
|
EU/1/21/1535 |
24.2.2023 |
||
|
24.2.2023 |
Adcirca |
|
EU/1/08/476 |
27.2.2023 |
||
|
24.2.2023 |
Emselex |
|
EU/1/04/294 |
1.3.2023 |
||
|
24.2.2023 |
Febuxostat Mylan |
|
EU/1/17/1194 |
27.2.2023 |
||
|
24.2.2023 |
Pemazyre |
|
EU/1/21/1535 |
27.2.2023 |
||
|
24.2.2023 |
QINLOCK |
|
EU/1/21/1569 |
3.3.2023 |
||
|
24.2.2023 |
Rixathon |
|
EU/1/17/1185 |
27.2.2023 |
||
|
24.2.2023 |
Riximyo |
|
EU/1/17/1184 |
27.2.2023 |
||
|
24.2.2023 |
Ronapreve |
|
EU/1/21/1601 |
28.2.2023 |
||
|
24.2.2023 |
TUKYSA |
|
EU/1/20/1526 |
2.3.2023 |
||
|
24.2.2023 |
Wakix |
|
EU/1/15/1068 |
27.2.2023 |
||
|
27.2.2023 |
Abilify |
|
EU/1/04/276 |
7.3.2023 |
||
|
27.2.2023 |
Aflunov |
|
EU/1/10/658 |
28.2.2023 |
||
|
27.2.2023 |
Daptomycin Hospira |
|
EU/1/17/1175 |
28.2.2023 |
||
|
27.2.2023 |
Foclivia |
|
EU/1/09/577 |
28.2.2023 |
||
|
27.2.2023 |
NUBEQA |
|
EU/1/20/1432 |
28.2.2023 |
||
|
27.2.2023 |
Reblozyl |
|
EU/1/20/1452 |
28.2.2023 |
||
|
27.2.2023 |
Reblozyl |
|
EU/1/20/1452 |
28.2.2023 |
||
|
27.2.2023 |
Sprycel |
|
EU/1/06/363 |
28.2.2023 |
||
|
27.2.2023 |
Tecentriq |
|
EU/1/17/1220 |
28.2.2023 |
||
|
27.2.2023 |
Venclyxto |
|
EU/1/16/1138 |
28.2.2023 |
||
|
27.2.2023 |
Voriconazole Accord |
|
EU/1/13/835 |
28.2.2023 |
— Withdrawal of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
|
23.2.2023 |
Pregabalin Zentiva k.s |
|
EU/1/16/1166 |
24.2.2023 |
— Modification of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council; Article 5 of Regulation (EU) 2019/6 of the European Parliament and of the Council): Accepted
|
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
||
|
2.2.2023 |
Tulissin |
|
EU/2/20/252 |
6.2.2023 |
||
|
3.2.2023 |
Forceris |
|
EU/2/19/235 |
6.2.2023 |
||
|
3.2.2023 |
Locatim |
|
EU/2/99/011 |
9.2.2023 |
||
|
3.2.2023 |
Panacur AquaSol |
|
EU/2/11/135 |
7.2.2023 |
||
|
6.2.2023 |
Apoquel |
|
EU/2/13/154 |
7.2.2023 |
||
|
6.2.2023 |
CLYNAV |
|
EU/2/16/197 |
7.2.2023 |
||
|
6.2.2023 |
Procox |
|
EU/2/11/123 |
8.2.2023 |
||
|
6.2.2023 |
Procox |
|
EU/2/11/123 |
7.2.2023 |
||
|
6.2.2023 |
Versican Plus DHPPi/L4R |
|
EU/2/14/163 |
7.2.2023 |
||
|
9.2.2023 |
MiPet Easecto |
|
EU/2/17/220 |
14.2.2023 |
||
|
20.2.2023 |
Advocate |
|
EU/2/03/039 |
22.2.2023 |
||
|
20.2.2023 |
Bovela |
|
EU/2/14/176 |
22.2.2023 |
||
|
20.2.2023 |
GALLIPRANT |
|
EU/2/17/221 |
21.2.2023 |
||
|
20.2.2023 |
Suvaxyn Circo + MH RTU |
|
EU/2/15/190 |
23.2.2023 |
||
|
23.2.2023 |
Locatim |
|
EU/2/99/011 |
1.3.2023 |
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
|
European Medicines Agency |
|
Domenico Scarlattilaan 6 |
|
1083 HS Amsterdam |
|
NETHERLANDS |